Thermo Fisher Scientific (NYSE:TMO) PT Raised to $640.00

Thermo Fisher Scientific (NYSE:TMO) had its price target upped by research analysts at The Goldman Sachs Group from $550.00 to $640.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. The Goldman Sachs Group’s target price would suggest a potential upside of 11.44% from the stock’s current price.

A number of other analysts also recently commented on TMO. Citigroup started coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Robert W. Baird reiterated an “outperform” rating and set a $670.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Raymond James boosted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Finally, Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $601.56.

Thermo Fisher Scientific Trading Up 0.1 %

Shares of TMO stock opened at $574.31 on Wednesday. The business’s fifty day moving average price is $571.39 and its 200 day moving average price is $525.37. Thermo Fisher Scientific has a 1-year low of $415.60 and a 1-year high of $603.82. The firm has a market capitalization of $218.99 billion, a PE ratio of 37.17, a P/E/G ratio of 2.43 and a beta of 0.80. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. Thermo Fisher Scientific’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $5.40 earnings per share. As a group, sell-side analysts forecast that Thermo Fisher Scientific will post 21.52 EPS for the current fiscal year.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently bought and sold shares of TMO. Halpern Financial Inc. grew its stake in Thermo Fisher Scientific by 307.7% during the 3rd quarter. Halpern Financial Inc. now owns 53 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 40 shares in the last quarter. Northwest Financial Advisors bought a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. True Wealth Design LLC lifted its holdings in Thermo Fisher Scientific by 1,275.0% during the 4th quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock worth $29,000 after buying an additional 51 shares during the last quarter. Coppell Advisory Solutions LLC bought a new position in Thermo Fisher Scientific during the 2nd quarter worth approximately $33,000. Finally, Live Oak Investment Partners bought a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $36,000. Institutional investors and hedge funds own 89.23% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.